Skip to main
  1. Stocks
  2. Fennec Pharmaceuticals
  3. Forecast
FENC

Fennec Pharmaceuticals (FENC) Stock Forecast & Price Target

Fennec Pharmaceuticals (FENC) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fennec Pharmaceuticals is benefiting from accelerating adoption of PEDMARK as the expanded commercial organization drives deeper utilization, higher vials per account, and stronger demand across new and existing accounts, with 2Q26 net product sales rising to $17.2M, up 78% year over year. Its outlook is further supported by improving operating leverage, as total revenue reached $17.9M in 2Q26, non-GAAP adjusted EBITDA turned positive at $2.8M, and cash and equivalents stood at $41.2M, signaling a stronger financial base. Longer-term upside also comes from potential NCCN reclassification by early 2028 and possible Japan entry in 2027, while the absence of current European revenue leaves room for additional royalty and international contribution.

Bears say

Fennec Pharmaceuticals is exposed to a highly fragile investment case because 100% of revenue comes from PEDMARK, leaving no pipeline diversification and forcing any expansion to depend on external partnerships or dilutive financing. Patent litigation risk is especially damaging because an unfavorable outcome could shorten exclusivity, while commercial growth still hinges on faster AYA account activation, formulary access, and reimbursement support despite pediatric economics that favor compounded STS at 70-90% discounts. Financially, cash was $42M as of December 2025, but the ongoing commercial buildout raises the cost base and leaves the company vulnerable if revenue underperforms, increasing the likelihood of further capital needs and volatility.

Fennec Pharmaceuticals (FENC) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fennec Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Fennec Pharmaceuticals (FENC) Analyst Forecast & Price Prediction

Get the latest Fennec Pharmaceuticals (FENC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Fennec Pharmaceuticals (FENC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fennec Pharmaceuticals (FENC) Forecast

Analysts have given Fennec Pharmaceuticals (FENC) a Buy based on their latest research and market trends.

According to 4 analysts, Fennec Pharmaceuticals (FENC) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fennec Pharmaceuticals (FENC)


Fennec Pharmaceuticals (FENC) Analyst Forecast & Price Prediction

Get the latest Fennec Pharmaceuticals (FENC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Fennec Pharmaceuticals (FENC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover FENC stock data and trends